Abstract
Administrative data from Florida Medicaid fee-for-service recipients under 2 years of age were reviewed for 7 seasons of respiratory synctial virus (RSV) activity and utilization of palivizumab prophylaxis (PP) prior to requirement for authorization. Utilization for certain indications (eg, chronic lung disease), following prematurity and gestational age at birth of <32 weeks, was modest; approximately two-thirds of eligible patients received prophylaxis. Infants with multiple indications had higher (approximately 80%) utilization of PP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
